ICOS and colorectal carcinoma: Chu et al computationally screened 14 immune checkpoint genes and validated them with IF, HE, and IHC and found that inducible T-cell stimulating factor (ICOS) was highly correlated with the survival and clinical characteristics of CRC patients.[24] The increased presence of tumor-infiltrating dendritic cells (DCs) in head and neck cancer, NSCLC, and CRC has been associated with improved progression-free survival.[25–27] These studies indicated that several immune cells are associated with prognostic of CRC.